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Abstracts of invited papers
Molecular targets for cancer therapy
K. Sikora
Department ofClinical Oncology, Royal Postgraduate Medical
School, Hammersmith Hospital, London W12 ONN, UK.
There are currently three major problems in treating patients
with solid tumours: the assessment of the state of the disease;
the lack of new effective systemic therapies and the poor
selectivity of current agents. Recent advances in molecular
genetics have uncovered new targets for therapeutic develop-
ment. These include growth factors, growth factor receptors,
membrane transduction systems, cytoplasmic signal processes
and transcription control. The elucidation of the function of
dominantly acting oncogenes and tumour suppressor genes
provide a key to a new era of molecular-based phar-
macological development.
There are several possibilities for the gene therapy of
cancer. The first clinical experiment has already been per-
formed involving the insertion of active tumour necrosis
factor genes into tumour infiltrating lymphocytes from a
patient with melanoma. Such systems all rely heavily on
tumour infiltration by appropriately manipulated cells. A
more sophisticated gene therapy system involves the insertion
of deleterious genes into vectors which can only be expressed
in the tumour or cells of the same tissue of origin when not
essential for the body as a whole. CEA, AFP, amylase,
calcitonin and prostate specific antigen provide examples of
such selectively expressed proteins. Retroviral shuttle vectors
containing the relevant tumour or tissue specific promoter
linked to a potentially toxic product can be constructed in
such a way as to only be expressed when inserted into cells
which have the necessary transcriptional machinery.
The manipulation of the somatic cell genetics of cancer
cells in vivo is becoming possible by the use of informational
drugs which can downregulate the expression of specific
genes. It may also be possible in future to replace defective
tumour suppressor genes which may reverse at least part of
the malignant phenotype.
The role of heparin binding growth factors in the malignant
progression of human breast cancer
M.E. Lippman, A. Wellstein, F. Kern, S. McLeskey & M.
Gottardis
Lombardi Cancer Research Center, Washington, DC 20007,
USA.
Our laboratory has been investigating the role of secreted
growth factor activities in autocrine and paracrine progres-
sion of human breast cancer. A survey oftumorigenic human
breast cancer cell lines reveals that all secrete heparin binding
growth factors capable of inducing clonogenic growth of
SW-13 human adrenal carcinoma cells dependent upon
fibroblast growth factors for their growth. A variety of
known members of the fibroblast growth factor family cont-
ribute to these activities as well as yet unidentified activities.
We have recently purified, sequenced and cloned a novel
heparin binding growth factor produced by some human
breast cancer cells which has potent angiogenic potential. In
addition, transfection of an expressiLon vector for fibroblast
growth factors into human breast cancer cells converts them
from hormone dependent to hormone independent growth in
athymic nude mice as well as permitting them to form
hematogenous metastases. A series of strategies based on
binding of heparin binding growth factors to polysaccharides
and inhibition of ligand interaction with receptor have been
developed which show substantial in vitro and in vivo
antitumour and chemoprevention activities with encouraging
therapeutic indices. One of these has been brought into
clinical trial for patients with advanced cancer. In summary,
heparin binding growth factors appear to play a critical role
in both autocrine growth of some breast cancers as well as
autocrine promotion of angiogenesis. Interference with these
pathways is associated with substantial antitumour activity
and is an interesting potential target for breast cancer
therapy.
Exploiting the ras oncogene
The following companies and associations have been major cont-
ributors to this meeting: Amgen Roche, Boehringer Ingelheim (Hos-
pital division), Boehringer Mannheim UK Pharmaceuticals, Book-
show Ltd, Bristol-Myers Squibb, Ciba Geigy Pharmaceuticals,
Degussa Pharmaceuticals Ltd, Eurocetus UK Ltd, Farmitalia Carlo
Erba Ltd, Lederle Laboratories, Merrell Dow Pharmaceuticals Ltd,
Nucleotron Trading Ltd, Schering Plough Ltd, Smithkline Beecham,
Wisepress Ltd.
N.R. Lemoine
ICRF Oncology Group, Cyclotron Building, Hammersmith
Hospital, Du Cane Road, London W12 OHS, UK.
The three members of the ras oncogene family are activated
by specific point mutations in a wide range of human
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tumours. The frequency of activation and the identity of the
ras oncogene affected vary dramatically between tumour
types: 75% of pancreatic cancers have mutations affecting
only Ki-ras codon 12 and 50% of thyroid tumours have
mutations affecting all three oncogenes at codon 12, 13 or 61,
while breast cancers and female genital tract tumours do not
have ras mutations. Activation of ras oncogenes often repre-
sent an early critical event in tumorigenesis, and has a power-
ful dominant transforming effect on epithelial cells in vitro.
Identification of ras mutations may be a useful marker for
diagnosis of some malignant disease, particularly in situa-
tions where only cytological material is available. The
presence of ras mutations may be a marker ofpoor prognosis
at least in non-small cell lung cancer. New understanding of
the mechanisms involved in the processing and control of ras
proteins and of their connections in signal transduction path-
ways has identified potential targets for therapeutic interven-
tion. These include interference with synthesis and post-
transcriptional modifications required for membrane localisa-
tion, interference with the GTP/GDP exchange and GTP
hydrolysis, blocking of effector molecule function and
exploitation of mutant ras peptides as targets for immune
therapy.
p2lras: from onco-protein to signal transducer
J.L. Bos', R.H. Medema', B.M.Th. Burgering', A.M.M. de
Vries-Smits' & G.J. Pronk'
'Laboratoryfor Physiological Chemistry, Univesity of Utrecht,
Utrecht, The Netherlands.
p21ras.proteins are small G-proteins which cycle between a
GDP-Sound inactive conformation and a GTP-bound active
conformation. The proteins play an important role in signal
transduction, but the details are still elusive. Genes encoding
p2lras proteins are frequently mutated in human tumors.
These mutations abolish the intrinsic GTPase activity of the
encoded protein, relating in the malfunctioning of p2lras.
Our aim is to investigate the consequences of this malfunc-
tioning for the control of cell proliferation. We have chosen
fibroblasts as a model system and we have investigated in
which growth factor signal transduction pathway p2lras is
involved.
Previously, we have suggeted a possible involvement of
p2lras in the insulin signal transduction pathway in rat
fibroblasts. Recently, we obtained firm evidence for this
hypothesis by measuring the effect of insulin stimulation on
the activation of p2lras in NIH/3T3 cells overexpressing the
insulin receptor. A conversion of rasGDP into rasGTP (20 to
70% GTP as percentage of total nucleotides bound) was
found within 1 min after insulin stimulation. Using cells
overexpressing high levels of EGF- or PDGF-receptors, we
were not able to detect a significant shift in the GTP/GDP
ratio after stimulation with EGF or PDGF, stressing the
specificity of insulin in the activation of p2lras (Burgering et
al., EMBO J. 10, 1991, 1103). Using dominant inhibitory
mutants of p2lras we have investigated which cellular effect
of insulin stimulation is mediated by p2lras. We found that
these mutants inhibit insulin-induced activation of the c-fos
promoter (Medema et al., Mol. Cell. Biol, in press). We
conclude from our results that p21ras is involved in insulin-
induced signal transduction, in particular in the induction of
gene expression. Our results do not exclude a role of p2lras
in other signal transduction pathways. Two possible
mechanisms of insulin-induced activation of p2lras exist.
First, insulin could activate an exchange factor, which subs-
titutes GTP for GDP. Secondly, insulin could inhibit the
GTPase activating proteins p120GAP and NF1. An indica-
tion that P120GAP may mediate insulin-induced activation
of p2lras was obtained using the putative phosphatase
inhibitor phenylarsine oxide. This compound revealed an
insulin-induced phosphorylation of pl20GAP on tyrosines.
We, therefore, propose a model in which pl20GAP mediates
insulin-induced activation of p2lras.
myc, max and a novel rlf-L-myc fusion protein in small-cell
lung cancer
K. Alitalo, T.P. Miakel'a, P.J. Koskinen, I. Va'strik, G. Evan',
M.G. Borrello2, M. Shiraishi3 & T. Sekiya
Laboratory of Cancer Biology, University of Helsinki,
'Imperial Cancer Research Fund, London; 2Istituto Nazionale
dei Tumori, Milan; 3National Cancer Center Research Ins-
titute, Tokyo.
Max is a recently characterized basic/helix-loop-helix/leucine
zipper protein, which forms a sequence-specific DNA-binding
complex with the Myc family proteins (Blackwood and
Eisenman, Science 251, 1211, 1991). We have found a novel
Max cDNA which contains the sequences encoding the
DNA-binding and dimerization motifs, but lacks both the
putative regulatory domain and the nuclear translocation
signal of Max. AMax retains the ability to form a sequence-
specific DNA-binding complex with Myc, but is exclusively
cytoplasmic in the absence of Myc. When tested in vivo in a
rat embryo fibroblast Myc/ras cotransformation assay
AMax enhances transformation whereas Max causes a
decrease in the number of transformed foci. We suggest that
the Max gene encodes both a negative (Max) and a positive
(AMax) regulator of Myc function.
Oncogenic activation of myc genes in human cancer
involves deregulated expression of myc. Oncogenes of the
myc family are activated in several types of human tumors as
a result of gene amplification or chromosomal translocation.
We have recently characterized a gene fusion and a chimeric
protein product formed by L-myc and a part of a novel gene
named rlf in two small-cell lung cancer (SCLC) cell lines.
Although the chimeric mRNAs were shown to be identical,
they result from distinct DNA rearrangements at lp32.
Similar in vivo rearrangement involving rlf and L-myc have
been found in a number of cell lines and a primary SCLC
tumor. In addition, we have found coamplification of L-myc
and rlfwithout visible rearrangements in either gene in other
SCLC tumors.
Epidermal growth factor receptor in bladder and breast cancer:
relation to p53 expression and target for therapy
A.L. Harris', E. Horak2, S. LeJeunel, D. Neal3, K. Smith', R.
Leek', K. Mellon3 & C. Wright4
'ICRF Institute of Molecular Medicine, John Radcliffe Hos-
pital, Oxford; 2Department of Histopathology, John Radcliffe
Hospital, Oxford; 3Department of Urology, Freeman Hospital,
Newcastle upon Tyne; 4Department of Pathology, Royal Vic-
toria Infirmary, Newcastle upon Tyne.
Expression of EGF receptor was assessed in 111 primary
breast cancers by ligand binding, and compared with p53
expression detected by the antibody PAB240. There was a
significant association of p53 expression with EGF receptor
expression and inverse relationship with oestrogen receptor
expression and p53. There was no association with lymph
node status.
A similar study on 82 patients with primary transitional
cell cancer of the bladder using immunochemistry showed
that 18% of the tumours were positive with p53 with strong
staining and a further 36% with weaker staining, giving 54%
positive tumours. 31% showed staining for the EGF receptor
and 15% for cerbB-2. There was a strong association of
tumours invading the bladder muscle with p53 and EGFr
staining. However, there was no association between p53 and
EGF receptor expression.
EGF receptors were assessed on relapsed and recurrent
bladder cancers, approximately half the tumours were
positive. Using the toxin TGF alpha PE40, high affinity970 JOINT WINTER MEETING REPORT
binding sites were demonstrated with a slightly lower affinity
compared to EGF. This toxin was also inhibitory to breast
cancer cell lines proportional to the level of expression of
EGF receptor. These results suggest that a sub-group of
invasive bladder tumours could be treated by intravesical
cycle therapy with TGF alpha PE40. Similarly, the high
expression of p53 in poor prognosis breast cancer and blad-
der cancer suggests that approaches involving immunological
therapy should be evaluated. To assess whether this would be
feasible, a study of the loss of HLA in p53 positive tumours
was undertaken in breast cancers. Approximately one third
of the patients with HLA A2 showed loss of specific class
one HLA molecules. However, the majority of patients still
showed the expression of this class one molecule, and
therefore would be candidates for immunotherapy.
Biochemical and clinical applications of monoclonal antibodies
against the EGF receptor
J. Mendelsohn
Memorial Sloan-Kettering Cancer Center and Cornell Univer-
sity Medical College, New York, NY 10021, USA
We have produced anti-EGFR monoclonal antibodies
(MAbs) which block the binding of EGF and TGF-alpha,
and can prevent ligand-stimulated activation of EGFR
tyrosine kinase. These MAbs have been useful in studies of
EGFR function. Experiments utilizing the MAbs to block
ligand binding have demonstrated that autocrine stimulation
of EGFR phosphorylation can occur via an extracellular
pathway, involving TGF-alpha-mediated activation of EGFR
on the surface of the cell. The capacity of anti-EGFR MAbs
to inhibit cell proliferation has provided evidence for an
autocrine stimulatory pathway in cultures of malignant
human skin, breast, colon, lung, prostate and kidney cells.
Growth of human tumor xenografts can be inhibited in
situations where autocrine dependency is demonstrable in cell
culture. Imaging studies with anti-EGFR MAb labeled with
"' Indium demonstrated selective uptake in xenografts exp-
ressing high receptor levels. Based on these observations, a
phase I trial was carried out with "' In-labeled anti-EGFR
MAb 225 IgGI in patients with advanced squamous cell lung
carcinoma, a tumor which invariably expresses large numbers
of EGFR. Escalating doses of 225 IgGI were administered as
a single intravenous injection over one hour. A dose of
120 mg 225 IgGI could produce saturating antibody levels in
the serum for >3 days and successfully imaged primary
tumors as well as metastases > 1 cm in diameter, without
producing toxicity. The tumor uptake determined by area-of-
interest scanning was 3.4% of the injected dose, and there
was considerable uptake in the liver. This study establishes
the principle that anti-EGFR agents which block receptor
function can be safely administered to patients and will
localize, preferentially, to tumor cells bearing high levels of
EGFR. Further studies are exploring the potential efficacy of
repeated doses of anti-EGFR MAbs, combinations of
antireceptor MAbs, and combined MAb plus chemotherapy.
1991 Gordon Hamilton-Fairley Memorial
Lecture
Oncogenes and tumor suppressor genes
R.A. Weinberg
Whitehead Institute for Biomedical Research, 9 Cambridge
Center, Cambridge, MA 02142, USA.
Oncogenes have been studied intensively over the past decade
as important determinants of tumor outgrowth. In large part,
these genes encode proteins that participate in various ways
in the cell's mitogen-response pathway. The various onco-
proteins appear to release mitogenic signals constitutively,
and in so doing render the cell independent from normally
required mitogen stimulation.
Tumor cells must also acquire a second type of growth
deregulation, in that they must become non-responsive to
growth-inhibitor signals that are present in their environ-
ment. Several mechanisms may intervene here. Thus, they
may shed receptors for anti-mitogenic signals. Alternatively,
they may lose signal-transducing intracellular proteins. The
examples of the TGF-,B receptors and the retinoblastoma
gene product will be explored in some detail. Products of
tumor suppressor genes confer responsiveness to anti-
mitogenic signals and the inactivation of these genes is often
critical for tumor outgrowth.
Transcription factors in growth control and oncogenesis - an
overview
H.C. Hurst
ICRF Oncology Group, Cyclotron Building, Hammersmith
Hospital, Du Cane Road, London W12 OHS, UK.
Cellular growth and differentiation are regulated by
numerous proteins whose role is to transduce signals,
received at the membrane, across the cell to the nucleus. The
proteins that mediate these signals within the nucleus are
transcription factors whose role is to bind specifically to the
promoter regions of their cognate genes and influence the
rate of expression of that gene. Both positively and
negatively acting factors are known and indeed some factors
may have both activities in different situations. Our current
knowledge about how transcription factor activity may be
regulated will be reviewed. This includes information on how
transcription factors in general are controlled and also how
oncogenic versions of these proteins escape this regulation
thus contributing to uncontrolled patterns of growth during
oncogenesis. Finally, recent data from studies on
chromosomal breakpoints associated with human leukaemias
will be discussed. This has revealed that novel proteins
representing chimeras of two different transcription factors
can result from these translocations and the presence of these
proteins contributes fundamentally to the transformed state.
Regulation of cell growth, differentiation and death by myc
G. Evan
Imperial Cancer Research Fund, London.
Abstract not received
A genetic screen for SRF/SRE binding proteins
S. Dalton & R. Treisman
Transcription Laboratory, Imperial Cancer Research Fund,
Lincoln's Inn Fields, London, WC2A 3PX, UK.
Serum Response Factor (SRF) is a 67 kD phosphoprotein
that binds to the Serum Response Element (SRE) found in
the promoters of the c-fos and several other immediate-early
genes (1). Recent work indicates that SRF acts to recruit to
the SRE an accessory protein, p62/TCF; although p62/TCF
alone does not bind the SRE, in the ternary complex it
makes DNA contacts at the SRE left side (2). In Balb/C3T3
cells p62/TCF binding appears to link the c-fos SRE to the
protein kinase C dependent signal transduction pathway (3).
A genetic screen using yeast for the isolation of mam-
malian cDNAs that encode protein that can interact withJOINT WINTER MEETING REPORT 971
SRF at the c-fos SRE will be presented. A reporter strain
was constructed that contains a chromosomal lacZ indicator
gene placed under control of a UAS consisting of a c-fos
SRE derivative. Transformation of this strain with plasmids
encoding SRF showed that full length SRF activated the
indicator only 4-fold in the presence of galactose, while an
SRF-VP16 fusion showed a galactose-dependent induction of
more than 100-fold. A library of randomly primed cDNAs
from HeLa cell mRNA was constructed in a vector that
expresses the cDNAs as fusions with the potent acidic trans-
cription activation domain of the HSV VP16 protein. The
library was transformed into the indicator strain and colonies
that activated the reporter gene identified by P-galactosidase
color assay. cDNAs were recovered that activated the
reporter gene in both an SRF-dependent and -independent
fashion. The structure and properties of the encoded proteins
will be discussed.
References
TREISMAN, R. (1990) Seminars in Cancer Biology, 1, 47.
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Constance Wood Memorial Lecture
Retinoid receptors in development and disease
R.M. Evans*', A. Kakizuka, S. Kliewer, D. Mangelsdorf &
K. Umesonol
Howard Hughes Medical Institute', The Salk Institute, La
Jolla, CA 92037.
The cellular responses to RA are mediated by two families of
transcription factors, which include the RA receptors (RARs)
and the retinoid X receptors (RXRs). Although both RAR
and RXR respond specifically to RA, they differ substantially
from one another in primary structure and ligand specificity.
A major question raised by the discovery of two retinoid-
responsive systems is whether their functions are indepen-
dent, interactive, or redundant. One approach to answer this
question is to determine whether they share common or
distinct downstream target genes. In regard to target
sequences we have recently described properties of direct
repeats (DRs) of the half-site AGGTCA as hormone res-
ponse elements. According to our results, spacing of the
half-site by 3, 4, or 5 nucleotides determines specificity of
response for vitamin D3, thyroid hormone and retinoic acid
receptors, respectively. This so-called '3-4-5' rule suggests a
simple physiologic code exists in which half-site spacing plays
a critical role in achieving selective hormonal response. As
part of these studies, we have also identified that the RXR,
but not the RAR, is able to activate through a direct repeat
spaced by one nucleotide. In contrast, both RAR and RXR
are able to commonly activate through a DR with a spacing
of 5. Evidence that RXR heterodimers modulate the RA
response will be presented. Finally we will discuss the isola-
tion and characterization of a fusion product produced as a
consequence of a t(15:17) translocation characteristic of
human acute promyelocytic leukemia. This translocation
which occurs in the retinoic acid receptor gene generates a
unique mRNA which encodes a fusion protein between the
retinoic acid receptor alpha (RARa) and a myeloid gene
product called PML. Structural analysis reveals that the
PML protein is a member of newly recognized protein family
that includes a variety of putative transcription factors as
well as the recombination-activating gene product (RAG-i).
The abberant PML-RAR fusion product, while typically
retinoic acid responsive, displays both cell type and promoter
specific differences from the wild type RARo. Because
patients with APL can be induced into remission with high
dose RA therapy, we propose that the non-liganded PML-
RAR is a new class of dominant negative oncogene product.
Abstracts of members' proffered
papers
The importance of serum concentrations on the efficacy and
toxicity of suramin in patients with advanced cancer
J. Wagstaff', R.E.N. van Rijswijk', A.C. van Loenen2, R.
Lopez', C.J. van Groeningen', J.J. Heimans3 & H.M. Pinedo'
'Department Medical Oncology, 2Department Pharmacy,
3Department Neurology, Free University Hospital, 1007 MB
Amsterdam, The Netherlands.
Aberrations in growth factor activity have been clearly im-
plicated in the promotion of cancer cell proliferation.
Suramin (Sur) has the ability to interfere with these processes
in vitro and consequently the drug has been explored as a
new anticancer agent in the clinic. Sur levels of >200 mg/L
have generally been required before anti-tumour responses
have been observed whilst levels > 300 mg/L have been
associated with disabling neurotoxicity. This narrow
therapeutic window has meant that the control of serum Sur
levels has become a crucial issue in the clinical development
of this drug. The terminal plasma half life of Sur is 45-55
days which makes a loading regimen designed to achieve
therapeutic serum levels (200-300mg/L) followed by inter-
mittent maintenance treatments rational.
We have examined the pharmacokinetics of 5 loading
regimens in an attempt to discover the optimum schedule for
sur. 1-1.5 gm/week for 3 to 6 weeks produced levels
>200mg/L in only one patient (pt) whilst 3/6 developed
progressive disease before this level was obtained. 350mg/m2/
day, as a continuous infusion (4 pts) produced levels of
160-247 mg/L after 6 to 14 days whilst 600mg/m2/day (4
pts) gave levels of 264-381 in 3-5 days. This latter dose if
given by 6 (13 pts) or 12 (5 pts) hour infusion may give peak
levels in excess of 400 mg/L after 3 to 5 days.
The weekly maintenance treatments were based on the
trough Sur levels and varied from 300 to 900 mg/m2. There
was a linear relationship between these doses and the mean
increase produced. A regression line drawn through these
mean values has an r value of 0.999 (<0.0001). Using these
data and knowing the trough and target (_300 mg/L) Sur
levels it is possible to calculate how much Sur to give. Using
a continuous infusion loading regimen of a few days duration
and the above data to calculate the maintenance doses it is
possible to maintain the Sur levels within the narrow
therapeutic window. Studies conducted until now have failed
to adequately achieve this. Further studies are indicated in
order to determine the efficacy and toxicity of Sur when the
drug levels are maintained within this narrow therapeutic
window.
Sequential interleukin 2 and alpha interferon for renal cell
cancer and melanoma
H. Thomas, C. Barton, A. Saini, A. Dalgleish & J. Waxman
Department ofClinical Oncology, Royal Postgraduate Medical
School, Hammersmith Hospital, Du Cane Road, London W12
ONN, UK.
Unexpectedly high response rates to Interleukin 2 therapy
have been described in renal cell carcinoma and melanoma.972 JOINT WINTER MEETING REPORT
The consensus view is that the true response rate is lower
than initially reported and its toxicity, greater. There is a
theoretical basis for the synergy of interleukin 2 with other
cytokines. We have investigated sequential treatment with
interleukin 2 and alpha interferon. Thirty one patients with
metastatic renal cell carcinoma or melanoma have been
treated with continuous infusion recombinant interleukin 2
(Glaxo). One of twenty two patients had a partial response
and one a minimal response. None of nine patients with
melanoma responded to interleukin 2. Sixteen of seventeen
patients with renal cell cancer and eight with melanoma
subsequently received alpha interferon (Roche). Two patients
with renal cell cancer responded to alpha interferon with
sustained remissions of two and three years; both had res-
ponded to interleukin 2. The further investigation ofcytokine
combination therapy is suggested by these unusually long
responses to alpha interferon.
Cytogenetics of uveal melanoma
K. Sisley', D. Cottam2, G. Rennie2, A.M. Potter3, C.W.
Potter' & R.C. Rees'
'Department ECM and 'Department Opthalmology, Medical
School, Sheffield University; 3Centrefor Human Genetics, 117
Manchester Road, Sheffield.
Posterior uveal melanoma is an ocular tumour derived from
the ciliary body and choroid. We have studied 20 of these
ocular tumours of which 16 were successfully analysed.
Cytogenetic reports of this tumour have been limited, with
only 23 reported cases. We present the results from 16
tumours. Two tumours had a normal chromosome comple-
ment, and a second demonstrated loss of the Y chromosome
as the single abnormality. The remaining tumours presented
basically pseudodiploid karyotypes with only limited
chromosome changes. The most frequently involved
chromosomes were 3, 6 and 8. Seven tumours derived from
the ciliary body had non random association between
monosomy of chromosomes 3 and i(8q). Abnormalities of
chromosome 6 involving the long or short arms were found
in 9 tumours and two tumours also demonstrated deletion at
11q23.
Loss of heterozygosity (LOH) at the llpl5 locus in human
ovarian cancer.
D. Eccles', L. Gruber2, M. Steel2 & R. Leonard'
'Imperial Cancer Research Fund, Medical Oncology Unit,
2MRC Human Genetics Unit, Western General Hospital, Edin-
burgh EH4 2XU.
Detection ofareas ofthe human genome where allele loss is a
common feature of a particular type of tumour is a popular
method of identifying candidate tumour suppressor genes
(tsg). The hallmark of a tsg is inactivation of the gene at
both loci. LOH is frequently identified as one inactivating
event and once the tsg has been isolated and cloned, muta-
tions are usually identifiable in the retained copy. We have
examined 46 ovarian tumours with paired blood DNA sam-
ples for LOH at two loci in the llpl5 region, the c-Ha-ras
(1IpI5.5) locus and the more proximal calcitonin (CALC)
locus (1 lpl5.5). Out of 24 serous carcinomas allele loss at
1lpl5.5 was only 14% (2/14 informative tumours) compared
with 46% (5/11) at the CALC locus. Out of all types of
carcinoma, LOH at CALC was still significant at 33% com-
pared with the rate at the c-Ha-ras locus of 18% overall.
There may be a tsg at or near the CALC locus which is
implicated in the genesis of ovarian carcinoma. One out of 2
informative borderline tumours showed allele loss at CALC
but retained heterozygosity at the distal locus. The molecular
events involved in the development of borderline tumours
may be a step on the way to the development of frank
carcinoma.
Phosphomonoester and proliferation in human breast cancer
R. Kalra, K. Wade', M. Greenall2, R. Camplejohn', A.L.
Harris4 & G.K. Raddal
*MRC Radiobiology Unit, Chilton; 'Biochemical and Clinical
Magnetic Resonance Unit, 'Department Surgery and 'Clinical
Oncology, John Radcliffe Hospital, Oxford; and 'R. Dimbleby
Department Cancer Research, St Thomas' Hospital.
"P magnetic resonance spectroscopy (MRS) of tumours show
elevated levels of phosphomonoester (PME). The PME
region contains predominately the synthetic precursors of
membrane phospholipids, phosphoethanolamine (PE) and
phosphocholine (PC). Early changes in PME following
therapy of breast cancer have been demonstrated. In cultured
human breast cancer cells the levels of PE and PC are greater
during exponential growth than at confluence suggesting an
association between the PME content and proliferation.
PME/ATP was measured from localised phosphorus spec-
tra in 31 patients with early breast cancer undergoing
surgery. PE and PC concentration was calculated from high
resolution 31p spectra of tumour extracts obtained at surgery
including additional cases with poor in vivo spectral resolu-
tion. Tumour tissue was also taken for histology, and DNA
flow cytometry for calculation of S phase fraction (SPF) for
assessment of tumour proliferation. Mean PME/ATP was
1.65 (sd ± 0.86) with a greater concentration of PE than PC.
The mean SPF in 27 cases was 8.36% (sd ± 7.49%). There
was no correlation between PME/ATP, PE, PC and SPF or
histological grade.
The relative amounts of PE and PC depend not only on
proliferation rate but are also affected by the conditions of
growth and the cell line suggesting genetic differences.
Evaluation of cell kinetics of cervical carcinoma
B.S. Bolger', T.G. Cooke2, P.D. Stanton2, A.B. McLean' &
R.P. Symonds3
'Department ofMidwifery, Queen Mothers Hospital, Glasgow;
2Department of Surgery, Glasgow Royal Infirmary; 'Depart-
ment of Oncology, Western Infirmary, Glasgow.
Tumour cells kinetics may indicate prognosis and help to
predict response to chemo- or radio-therapy. We have sought
to establish the cell kinetics of cervical carcinomas, using the
newly available technique of in vivo bromodeoxyuridine
labelling.
Sixty patients with stages Ib-IVb cervical carcinoma were
given bromodeoxyuridine 6-8 h prior to tumour biopsy.
Disaggregated fixed nuclei were stained for bromo-
deoyxuridine and total DNA content, and analysed by flow
cytometry. The proportion of bromodeoxyuridine labelled
nuclei (the labelling index, LI), the length of S phase
(Ts), and the potential doubling time (Tpot) were then
derived.
Fifty two (87%) of tumours produced satisfactory results.
Median parameters were: LI 7.5% (range 1.1-22.5), Ts
13.0 h (range 7.4-21.5), Tpot 6.6 days (range 1.5-52.5).
Advanced tumours had significantly higher LI than early
stage lesions (LI median 8.4% vs 3.9%, p = 0.022, Mann
Whitney). Normal cervical tissue was obtained from 8
patients, and showed significantly lower LI (0.8%,
p<0.001), but no difference in Ts.
These preliminary results demonstrate the feasibility of
measuring cell kinetic parameters in patients on a routine
basis. Bromodeoxyuridine labelling index is associated withJOINT WINTER MEETING REPORT 973
tumour stage, but the length of S phase shows no variation
with stage or presence of tumour.
Oestrone sulphatase inhibitors as antitumour agents for
oestrogen-dependent breast cancer
A. Purohit, L. Duncan & M.J. Reed
Unit of Metabolic Medicine, St Mary's Hospital Medical
School, London W2 IPG, UK.
Approximately one third of human breast cancers are oest-
rogen dependent. Such tumours regress upon endocrine treat-
ment. Oestrone sulphate stimulates growth of breast tumours
via conversion to oestrone and oestradiol as shown by data
from a variety of in vitro and in vivo studies. Oestrone
sulphatase, the enzyme which converts oestrone sulphate into
oestrone, is consistently found in primary mammary car-
cinoma. This oestrone sulphatase pathway may, therefore, be
significant and perhaps the primary means of local produc-
tion of oestrone in breast tissues. We have synthesised and
evaluated a steroidal inhibitor of oestrone sulphatase.
Oestrone-3-methylphosphonothioate (EIMPT) was found
to competitively inhibit in vitro oestrone sulphatase activity
in both intact breast cancer cells and human placental tissue.
The Km for oestrone sulphate was 6.13ILM whereas the Ki
for EIMPT was 14.56gM in placental tissue. The IC50 values
when oestrone sulphate was used at a concentration of 10JLM
were: 43gM (placenta) and 360IM (breast tumour). The
development of inhibitors of oestrone sulphatase represents a
novel therapeutic approach to hormone-dependent breast
cancer.
Glycoprotein processing inhibitors may inhibit tumour metas-
tasis by potentiating anti-tumour imune responses
C. Galustian, S. Foulds, J.F. Dye & P.J. Guillou
Academic Surgical Unit, St Mary's Hospital Medical School,
London W2 JNY.
Swainsonine (SW) inhibits Mannosidase II during N-linked
glycoprotein processing. SW has recently been found to
inhibit metastasis in several murine tumour models and to
augment the expression of receptors for the lymphokine
Interleukin-2(IL-2) on lymphocytes. In this study we have
asked whether SW might achieve these antimetastatic effects
by potentiating anti-tumour immune responses. The effect of
SW on the generation of lymphokine-activated killer (LAK)
cells was examined by performing SW dose response curves
on the generation of LAK cells from human peripheral blood
mononuclear (PMN) cells in response to a fixed concentra-
tion of IL-2 (1000 units/ml) in vitro for 3 days. Data are
expressed as mean Area-under curve (AUC) units at each
concentration of SW. At a concentration of 21g/ml, SW
significantly augmented LAK activity from 138 AUC units to
166 (± SED 10) AUC units (P<0.05 by Student's t-test)
and was dose-dependant (P<0.05 by ANOVA, n = 6
experiments).
We also studied the effects of SW on the susceptibility of
tumour cells to killing by human LAK cells. COL0320
colorectal cancer cells were cultured for 3 days with varying
concentrations of SW before being used as target cells in the
LAK cell assay which used unmodified PMN activated for 3
days with 1000 units/ml IL-2 alone as the effector cells. The
results for these experiments were as follows:- (mean of 3
experiments)
Concn. SW (jug/ml
used to modify
COL0320 0 1.0 2.0 5.0 10.0
LAK(AUC units ±SED) 75 93 ± 6.9 100± 5** 94± 1.5** 90± 3.3
(**P<0.05 on comparison with control by paired t-test).
Thus SW significantly augments human LAK activity and
tumour cell susceptibility to LAK cells at a concentration of
2 lg/ml. SW is non-toxic and may be an important reagent
for increasing the response rates of patients with malignant
disease to IL-2 therapy.
Activated polymorphonuclear neutrophils - mediators of the
interleukin-2 induced capillary leak syndrome?
C.H. Wakefield, P.D. Carey, S. Foulds, J. Monson & P.J.
Guillou
Academic Surgical Unit, St. Mary's Hospital Medical School,
London W2 JNY.
Interleukin-2 (IL-2)-based therapies provide both the greatest
response rates and prolongation of survival in patients with
advanced malignant melanoma (MM) and renal cell cancer
(RCC). Response rates are related to the total IL-2 dose
administered but the principal dose-limiting toxicity is a
capillary leak syndrome (CLS) of obscure aetiology which
predominantly afflicts the lung. Severe sepsis is also
associated with a similar acute lung injury which is mediated
at least in part by activated neutrophils. Tumour necrosis
factor (TNF) is a potent activator of neutrophils and may be
released during IL-2 infusion. We sought evidence for neut-
rophil activation in 10 patients with advanced MM or RCC
who developed CLS during a 5-day therapeutic infusion of
IL-2. Plasma TNFa levels were measured before (baseline)
and on days 1 and 5 of the infusion. Simultaneously, the
expression of the neutrophil activation marker CD llb and
neutrophil production of H202 were measured by flow cyto-
metry and are expressed as the mean (± SEM) of the mean
channel fluorescence (MCF) for each parameter.
Plasma TNFa H202 PRODN CD1lb expression
(pg/ml) (MCF) (MCF)
Baseline 7.8 1.3 103.2 4.5 75.4 ± 9.8
Day 1 53.9±10.1** 111.9± 3.7** 121.1 ± 18.9**
Day 5 28.3± 9.6 111.1±4.4** 197.6±34.1**
**p<0.05 by paired t-test on comparison with baseline data.
Plasma TNFa levels are elevated within 24 hours of begin-
ning IL-2 infusion and this is accompanied by phenotypic
and functional neutrophil activation. This is strong evidence
of a role for activated neutrophils in IL-2-induced CLS and
suggests means for modifying IL-2 toxicity without neces-
sarily diminishing its therapeutic efficacy.
Localisation of BHRFI to the mitochondria by immunoelectron
microscopy: implication for a role in preventing cell death by
apoptosis
T. Hickishl, C. Clarke2, D. Robertson2 & D. Cunningham'
'Section of Medicine, 2Section of Pathology; Institute of
Cancer Research, Royal Marsden Hospital, Sutton, Surrey.
BHRFI is an Epstein-Barr virus gene of unknown function
which is expressed at the interface between the latent and
lytic cycles'. Cell fractionation studies have indicated it is
associated with the mitochondria. BHRFI has 40%
homology with the bcl2 gene2 which is deregulated in at least
90% of cases of follicular non-Hodgkin's lymphoma. Bc12 is
expressed at the inner mitochondrial membrane and
deregulation appears to extend cell survival by interrupting
cell death by apoptosis3. BHRFI and bcl2 therefore may
have functional equivalence.
To explore the function of BHRFI we have examined an
EBV-genome positive cell line, B95.8, using low temperature
embedding immunoelectron microscopy. SU-DHL4, a cell
line which expresses bcl2 was also studied. B95.8 cells in log
phase growth were cultured in either standard (10% foetal974 JOINT WINTER MEETING REPORT
calf serum) or stressed (foetal calf serum absent) conditions
for three days. SU-DHL4 cells in log phase growth were
cultured in standard conditions. Cells were then pelleted,
washed, embedded in resin and 0.1 p sections prepared for
electron microscopy. Expression of BHRFI and bcl2 were
determined using the 5B11 and 100 antibody respectively.
Doubling % Viability BHRFI bcl2
time at 3 days expression expression
B95.8 Standard 24 hrs >95% 0.6% cells 0%
B95.8 Stressed 30 hrs >95% 3.5% cells NT
SU-DHL4 24 hrs >95% 0% >90%
B95.8 cells undergoing apoptosis could be identified by
their distictive nuclear chromatin pattern4 and these cells
contained clearly visible virions and were therefore in the
lytic cycle. The proportion of cells in the lytic cycle was
increased in the stressed B95.8 cells. Only B95.8 cells in the
lytic cycle expressed BHRFI and this was displayed at the
mitochondria. Mitochondria of lytic cycle B95.8 cells did not
cross react with 100.
One possible interpretation of this data would be that
BHRFI is expressed by EBV as it enters the lytic cycle to
extend the lytic cells' survival thus enabling maximum virus
production.
There is emerging detail of a pathogenic role for EBV in
Hodgkin's disease56. Currently we are exploring the pos-
sibility that BHRFI may promote Reed Sternberg cell sur-
vival.
This is the first demonstration of BHRFI expression at the
mitochondria and is an example of the utility ofimmunoelec-
tron microscopy for investigating gene function.
(5B1 1 was kindly provided by Dr G. Pearson and 100 was
a gift from Dr D. Mason).
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Weekly cisplatinum in combination as salvage for germ cell
tumour patients failing standard 3 weekly platinum based
regimes
M.A. Raja, R.T.D. Oliver, J. Ong & C.J. Gallagher
Department of Medical Oncology, The Royal London Hos-
pital, Whitechapel, London El JBB.
Recently there have been reports correlating chances of suc-
cess with standard 3 weekly platinum based regimes and an
index of tumour growth rate (Price - E.J. Cancer 1990; 26:
453) in malignant teratomas. Encouraged by several reports
in the literature that it was possible to give Cisplatin more
frequently than every three weeks (Merrin - J Urol 1978, 120:
73, Newlands - Lancet 1983; 1: 948, Wetlaufer - Cancer 1984;
53: 209), we have developed a regime alternating weekly BOP
with M-BOP.
Twenty-three patients with metastatic malignant teratoma,
4 relapsing after CR and 19 failing to achieve CR with
primary chemotherapy (6BEP(5), 8 EBCi (3), 8 EBCa (3),
and 1 Carboplatin), have been treated with this regime.
Patients received a median of 6 weeks of treatment with a
range of 3-10 weeks. 16 patients achieved CR, 11 of these
with surgery immediately following chemotherapy for
removal of residual masses (8 Retroperitoneal lymph node
dissection, and 3 thoracotomy out of which 6 showed foci of
mature teratoma, and 5 necrosis only). 11 of these continue
in CR with a median follow up of 14 months (range 6-60
months).
Prognostic significance of mitotic index and c-erbB2 oncogene
product in childhood medulloblastoma
R.J. Gilbertson', A.D.J. Pearson', E.B. Jaros2 & R.H. Perry
'Department of Child Health, Medical School, Newcastle upon
Tyne, NE2 4HH; 2Department of Neuropathology, Newcastle
General Hospital, Newcastle upon Tyne, NE4 6BE.
The prognostic significance of mitotic index (MI) and
c-erbB2 oncogene product expression of cells was inves-
tigated in 52 children with medullo-blastoma. The MI was
calculated for each case determining the percentage of non-
disputable mitotic figures within standard haematoxylin and
eosin sections prepared from all available tumour blocks.
Expression of the c-erbB2 oncogene product was detected
immunohistochemically using the monoclonal antibody
NCL-CB11 and the avidin biotin peroxidase complex techni-
que. Univariate analysis demonstrated a significant stepwise
decrease in patient survival with increasing MI. The 10 year
survival rates for the categories MI 0-2%, 2-3% and >3%
were 42%, 33% and 0% respectively (p<0.0001). Forty six
(83.6%) tumours were positive for the c-erbB2 protein. All
staining was abolished using antigen absorption controls.
Patients with more than 50% of tumour cells showing
c-erbB2 product positivity had a reduced survival (p<0.005)
- only 10% of these patients were alive at 10 years following
diagnosis compared to 55% of cases with less than 50%
positive cells. MI and c-erbB2 oncogene product expression
were analysed further using correlation statistics and mul-
tivariate survival analysis. A significant relationship between
tumour c-erbB2 protein expression and MI was observed
(p<0.001). When analysed together in multivariate analysis,
MI retained prognostic significance (p =0.004) whereas c-
erbB2 protein expression did not. Tumour MI represents a
highly significant independent prognostic factor for child-
hood medulloblastoma. C-erbB2 oncogene product expres-
sion is closely related to tumour MI but does not have
independent prognostic significance.
Abnormalities of the p53 tumour suppressor gene in pancreatic
cancer
C.M. Barton', S.L. Staddon', C.M. Hughes', P.A. Hall2, C.
O'Sullivan', G. Kloppel3, B. Theis4, R.C.G. Russell4, J.
Neoptolemos5, R.C.N. Williamson6 & N.R. Lemoine'
'ICRF Oncology Group, Hammersmith Hospital, London;
2Department of Histopathology, Hammersmith Hospital;
3Department of Pathology, Academic Hospital Jette, Free
University ofBrussels, Belgium; 4Department ofSurgery, Mid-
dlesex hospital, London; 5Department of Surgery, Dudley Rd
Hospital, Birmingham; 6Department ofSurgery, Hammersmith
Hospital, London; 7Cell Transformation Research Group, CRC
Laboratories, Department of Biochemistry, University of
Dundee, Dundee.
The tumour suppressor gene p53 has been found to be
mutated or inactivated at high frequency in several common
human tumours. Mutant forms of the p53 gene classically
cooperate with activated ras oncogenes to transform cells in
vitro. We have examined a series of exocrine pancreatic
carcinomas for overexpression of mutant forms of p53 by
immunohistochemistry with a panel of specific antibodies.
We found immunodetectable p53 in 13 of 22 (60%) frozen
pancreatic cancers and 7 of 13 pancreatic cell lines. One of
the antibodies, CMl1, recognises p53 in formalin-fixed,
paraffin-embedded archival material and using this reagent
we found immunodetectable p53 in 28 of 124 (23%) panc-
reatic cancers. We have successfully demonstrated the
presence of point mutations by direct sequencing of genomic
DNA extracted from archival tissue showing CM1
immunoreactivity. Overexpression of p53 protein was also
detectable in 5/13 pancreatic cancer cell lines byJOINT WINTER MEETING REPORT 975
immunoprecipitation and mutations in the p53 gene were
confirmed by direct sequencing of genomic and complemen-
tary DNA in these lines. Pulse chase analysis indicated that
the mutant protein has a prolonged half-life. We conclude
that p53 activation is an important event in human panc-
reatic tumourigenesis and that the CM1 antibody is of value
for the analysis of archival pathological material.
Mutation analysis of p53 in human normal, adenoma, diver-
ticular and carcinoma colorectal tissues
N.J. Froggatt', S.H. Leveson2 & R.C. Garner'
Cancer Research Unit, Department of Biology, University of
York, Heslington, YOJ 5DD, England; 'York District Hos-
pital, Wigginton Road, Y03 7HE, England.
Base substitution mutations in the p53 gene constitute one of
the most frequently occurring genetic lesions identified so far
in the multi-stage progression of cancer, having been found
in tumours originating from diverse tissue types. We have
examined paired normal and neoplastic human colorectal
tissues (both benign and malignant) for mutations in p53
using the polymerase chain reaction to amplify one region of
interest, comprising exons 5, 6, 7, and intervening introns.
Preliminary screening of amplified samples was carried out
using three restriction endonucleases, Cfo I, Hpa II, and Hae
III, which cleave in normal tissues at codons 175, 248 and
249, all sites at which mutations have previously been found.
Abnormal band patterns were seen in 7 of 20 tumour sam-
ples (1 adenoma and 6 carcinomas) as compared with corres-
ponding normal tissues, but not in diverticular samples.
Direct detergent-based sequencing of the PCR products
has confirmed these base substitution events, and has also
revealed mutations at codon 245, another common mutation
site. G.C to A.T transitions at CpG dinuleotides so far
predominate; C.G to T.A transitions have also been found.
This work adds significantly to the number of mutations
found in human colorectal neoplasms. It confirms the lack of
a single codon as a mutational hotspot, but supports the
hypothesis that GC-rich sequences are the loci most often
involved.
Implications of alterations in the structure of the p53 tumour
suppressor gene in human breast cancer
D.M. Barnes', C.J. Fisher', C.E. Gillett', R.R. Millis' & D.P.
Lane2
'ICRF Clinical Oncology Unit, Guy's Hospital, London, UK;
'CRC Labs, University of Dundee, Dundee, UK.
The p53 gene encodes a 393 amino acid nuclear phospho-
protein which is now thought to act as a tumour suppressor.
Alterations in the structure of the gene (usually either allele
loss and/or mutation) are common in many human cancers.
The wild type protein has a very short half-life and rapidly
disappears from the cell. Mutations, which appear to confer
stability, lead to abnormal acccumulation of protein which
can be detected immunohistochemically.
We have used polyclonal antibody CM-1 (Midgeley et al.,
manuscript submitted) raised against a construct of the entire
p53 protein, in an immunohistochemical study of breast car-
cinoma. Optimum conditions have been established for the
immunohistochemical detection of the protein in formalin
fixed paraffin-embedded tissue. Positive nuclear staining, ran-
ging from weak to very strong, is seen in approximately 70%
of cases of infiltrating carcinoma. Care must be taken when
interpreting lack of positive staining as this could occur
either when the p53 gene is unaltered or when both alleles
have been lost. Staining patterns have been related to tumour
morphology and a significant association has been found
between strong staining and poorly differentiated grade III
infiltrating ductal carcinomas.
Early work on ductal carcinoma in situ suggests a lower
incidence of positive staining than occurs in infiltrating
tumours. No relationship has been found, so far, between
staining for p53 and the morphology of the in situ tumours.
Mutations in exon 7 of the p53 tumour suppressor gene are not
pathognomonic of Li Fraumeni syndrome
J.M. Dunn', D.J. Hastrich', S. Nicholson', N.J. Maitland2 &
J.R. Farndon'
'Department of Surgery, Bristol Royal Infirmary, Bristol BS2
8HW; 'Department of Pathology, University of Bristol.
Abnormalities of the p53 tumour suppressor gene have been
detected in many human malignancies. Mutations have been
detected in specific regions of the gene and some may have a
significant role in malignant transformation and tumour pro-
gression. Germline mutations of the p53 gene at codons 245,
248, 252 and 258 have recently been detected in Li Fraumeni
syndrome. This syndrome is characterised by the association
of childhood sarcoma with an increased incidence of early
onset, multiple primary tumours of breast, brain, larynx,
bone, adrenal gland and leukaemia among family members.
One family demonstrating characteristics of Li Fraumeni
syndrome have been examined at the 17p locus by Southern
blot and PCR-SSCP (polymerase chain reaction single strand
conformation polymorphism) techniques. The family includes
a 16 year old female with glioblastoma, her brother with a
sarcoma at 19 years and mother with bilateral breast cancer
who had a mastectomy at 32 years.
The index case demonstrates loss of the paternal copy of
the 17p allele in brain tumour tissue. Screening the family by
PCR-SSCP of exons 5-8 inclusive revealed no germline
mutations the p53 gene. PCR sequencing of the index case at
exon 7 detected no base changes.
Mutations in exon 7 are not pathognomic of Li Fraumeni
syndrome. Loss of the normal paternal 17p allele in this
tumour may uncover p53 abnormalities in other exons which
merit further investigation.
Are inherited mutations of the p53 gene a general determinant
of familial breast cancer?
R. Eeles' 2, W. Warren2, B. Ponder4, D. Averill3, D. Easton3,
M. Ponder4, C. Cooper2 & J. Peto3
Departments ofAcademic Radiotherapy, Royal Marsden Hos-
pital', Molecular Carcinogenesis', and Epidemiology3, Institute
of Cancer Research, Surrey. CRC Human Genetics Unit,
Cambridge4.
Recent evidence links the Li-Fraumeni syndrome to inherited
mutations within exon 7 of the p53 gene*. Since an excess of
breast cancer is found in this syndrome, and somatically
acquired mutations of exons 5-9 of the p53 gene are a
common feature of sporadic breast cancer, these findings
have prompted speculation that germline p53 mutations may
be important in familial breast cancer. We have examined
lymphocyte DNA from 42 individuals with a strong family
history of breast cancer for germline mutations in exons 5-9
of the p53 gene. These individuals were from 26 families and
in all families the index case was <46 years old at diagnosis.
In 7 families there were 2 affected first degree relatives aged
<45 at diagnosis and in 12 families there were 3 affected
first degree relatives, 2 of whom were <45 at diagnosis. In
15 families, 2 affected members were examined. The PCR
amplification products of exons 5, 6, 7, and 8 + 9 were
examined by single-stranded conformational polymorphism
analysis (SSCP) and for exon 7 the PCR product, synthesised976 JOINT WINTER MEETING REPORT
using a biotinylated primer, was also solid phase-sequenced
using streptavidin-coated magnetic beads.
No germline mutations were detected by SSCP in exons
5-9 of the p53 gene. In addition, direct sequencing of exon 7
also failed to show any mutations. We therefore conclude
that most familial breast cancer is unlikely to result from
such mutations.
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Tumour heterogeneity of ras and p53 abnormalities in colorec-
tal carcinoma
M.I. Ahamed', D. Grimshawl, G.T. Williams2, M.C.A Pun-
tis', L.E. Hughes' & R.A. Padua3
Departments of 'Surgery, 2Pathology, 3Haemotology, Univer-
sity Hospital of Wales, Heath Park, Cardiff CF4 4XN.
The dynamic heterogeneity of colorectal tumours was
examined in terms of oncogene expression in 19 patients at
different stages of disease. RAS and p53 oncogenes were
studied in normal mucosa, adenomatous polyps, primary
tumour and nodal and liver metastases. RAS mutations at
codon 12 of KRAS were analysed using polymerase chain
reaction followed by hybridization with oligonucleotide pro-
bes. Alterations in p53 gene were analysed by enzymatic
digestion with two restriction enzymes. Hind III and Xbal,
and hybridisation with c DNA probes using the Southern
Blot technique. 15 specimens from 6 patients showed point
mutation at codon 12 of KRAS, 4/4 villous polyps, 0/2
tubular polyps, 4/18 primary cancers, 2 of 6 positive nodes
and 3 of 4 hepatic metastases. Nearly 50% of patients (9/19)
showed alteration of p53 gene, either restriction fragment
length polymorphism or allele loss in different tissue speci-
mens of 2 polyps, 9 primary tumour and 3 each of nodal and
liver metastases. Four patients had both RAS and p53 muta-
tions. While RAS and p53 oncogenes occurred in 32% and
50% of patients respectively, the mutation is not stable
throughout the disease process.
Differential regulation of growth and EGF receptor expression
by retinoic acid in prostatic cell lines of normal and neoplastic
origin
T.D. France & C.L. Eaton
Tenovus Institute for Cancer Research, Heath Park, Cardiff
CF4 4XX.
Although 70% of prostatic cancers respond to androgen
ablation as primary therapy, the disease is inevitably refrac-
tory to this treatment and the subsequent behaviour of these
tumours is indicative of increasing autonomy in respect of
growth. Several studies have suggested that EGF and related
peptides are important growth regulators in normal and
neoplastic prostatic cells. Retinoic acid is an established mor-
phogen and is potentially interactive with the action of
growth factors and subsequent signal transduction pathways.
We therefore investigated the proliferative effects of retinoic
acid and the concomitant influence upon expression of the
EGF receptor in prostatic epithelial cell lines.
In serum-free cultures of two poorly differentiated tumour
prostatic cell lines (PC3, DU145) retinoic acid was a
significant growth enhancer. In contrast, retinoic acid was a
growth suppressor in cell lines derived from normal tissue
(CAPE) and from a well differentiated tumour (CPA) and
abolished the potent growth promoting properties of EGF in
these cell lines. EGF receptor expression was measured at the
protein ([1251I]EGF saturation analysis) and mRNA (Northern
hybridisation) level. In CPA cells retinoic acid significantly
elevated EGF receptor expression, while in cells derived from
normal prostate (CAPE) retinoic acid decreased receptor exp-
ression. The effects of other agents, including androgens,
upon EGF receptor expression were also disparate.
These data suggest that differences in retinoic acid sen-
sitivity and EGF response pathways exist between prostatic
cell types of varying pathology.
Differential expression of oestrogen responsive genes in breast
cancer
D.L. Manning & R.I. Nicholson
Tenovus Institute for Cancer Research, Heath Park, Cardiff
CF4 4XX.
Our inability to accurately predict by ER status alone wheth-
er a given patient will respond to endocrine therapy has led
to the search for additional markers of hormone respon-
siveness.
We have prepared two cDNA libraries from the mRNA of
oestrogen stimulated breast cancer cells (ZR-75-1 and T-47D-
5). A total of ten genes (pLIV-1, pLIV-2 (pS2) and pSyd 1-8)
have been isolated whose mRNAs are increased by oestrogen
(2.5-16 fold) and reduced by antioestrogens. In order to
determine their potential as prognostic markers in the man-
agement of breast cancer we have measured the expression of
four genes (pLIV-1, pLIV-2; pSyd 3 and pSyd 8) in 118
primary breast tumours which were also immunohis-
tochemically assayed for ER, PgR, ErbB2, EGFR, Ki67 and
pS2. All four genes were expressed at higher levels in tumour
compared to those found in normal breast tissue and cell
lines. In addition, pSyd3 and 8 sequences were more abun-
dant than their pLIV-l & 2 counterparts. Both pLIV-1 and
-2 showed a strong correlation with ER status with expres-
sion increasing with increased cellular ER positivity. An
inverse relationship between ER and EGFR levels was
observed and was reflected in pLIV-1 and -2 mRNA levels
decreasing with increasing cellular EGFR staining. In con-
trast to pLIV-1 and pLIV-2, pSyd-3 and -8 were expressed in
both ER - and ER + tumours and showed increased exp-
ression with increasing cellular proliferatin as shown by Ki-
67 staining.
In conclusion, whilst pLIV-1 and pS2 levels appear to be
associated with estrogen responsive pathways, pSyd3 and 8
are more closely linked to cellular proliferation. Since an
increase in proliferation is associated with a loss of hormone
sensitivity (Nicholson et al., 1991, Eur. J. Cancer, 27, 908-
913) the increased levels of pSyd3 and 8 may play a role in
the transition from endocrine responsive to unresponsive
states.
Oestrogenic and anti oestrogenic actions of tamoxifen
analogues in rat mammary tumours in vitro and in vivo
A.L. Jarrett & S.A. Eccles
Institute of Cancer Research, Sutton, Surrey, UK.
Although clearly of great clinical value in the treatment of
breast cancer, Tamoxifen has been shown to be a partial
oestrogen agonist both in vitro and in vivo.
Using cell lines and clones of oestrogen-induced, and spon-
taneously arising hormone-responsive rat mammary tumours,
we have compared the oestrogenic and anti-oestrogenic
effects of Tamoxifen and two analogues. This has been
achieved by assaying drug action under conditions of
physiological hormone levels (antagonist assay) or of oest-
rogen deprivation (agonist assay).
In vitro, cell lines were selected which showed inhibition of
growth in the presence of phenol-red free medium and DCC
stripped FCS. Under these conditions, both Tamoxifen and
two analogues (Todo-tamoxifen and Pyrolidino-iodo-JOINT WINTER MEETING REPORT 977
tamoxifen) were able to stimulate growth, as did oestradiol.
In the presence of DMEM + 10% FCS (normal growth con-
ditions) Tamoxifen inhibited cell growth and both analogues
gave consistently better results.
In vivo tumours were implanted into OOX female rats. Cell
lines were chosen which, under these conditions, would not
develop without additional oestrogen. Groups of rats were
dosed with TAM compounds at 2.4mg/kg. Again we were
able to show similar oestrogenic effects of all 3 compounds,
although in normal animals, the two analogues have shown
greater inhibitory effects on tumour growth than the parent
compound.
These models offer a rapid and clinically relevant tumour
assay system in which to screen separately for oestrogenic
and anti-oestrogenic actions of new compounds.
C-erb-2 overexpression in human breast carcinoma cell lines
D. Hollywood & H.C. Hurst
ICRF Oncology Group, Cyclotron Building, Hammersmith
Hospital, Du Cane Road, London W12 OHS, UK.
This study investigates the mechanisms controlling the
overexpression of erbB-2 mRNA in human breast carcinoma
cell lines.
erbB-2 mRNA levels and gene copy number have been
examined by Northern Hybridisation, RNA slot blotting,
quantitation of erbb-2 mRNA half-life and Southern Hyb-
ridisation in a series of immortalised mammary epithelial cell
lines (B-HBL100, MTSV1.7, MRSV2.1, MRSV2.4) and
human breast carcinoma cell lines (ZR75-1, BT483, MDA
MB 175, SKBR3). Malignant cell lines which exhibit 4-8
fold erbB-2 mRNA overexpression from the single copy gene
have been identified.
The level of erbB-2 transcription was examined by nuclear
run-on assays. Comparison of a non-tumourigenic cell line
with baseline erbB-2 expression and malignant cell lines with
erbB-2 overexpression has demonstrated a 3-fold increase in
erbB-2 transcription in the malignant cell type.
Currently transcriptional control of the erbB-2 promoter in
both types of cell line is being examined by short-term trans-
fection of a series of erbB-2 promoter-CAT reporter gene
constructs. Our results will be presented.
Introduction ofoncogenes into the mouse mammary gland using
transplantation
J.M. Bradbury, S.E. Hiby, H. Sykes & P.A.W. Edwards
Department of Pathology, University of Cambridge, Tennis
Court Road, Cambridge, CB2 JQP.
We have developed a method for expressing genes specifically
in mouse mammary epithelium in vivo. Normal epithelial cells
are isolated from an adult mouse and maintained in culture
for four days. During this time, genes are introduced into the
cells using non-replicating retroviruses. The altered cells are
transplanted into the mammary fat-pad of another mouse
from which all the endogenous epithelium has been removed
by surgery (a cleared fat-pad). The transplanted cells recons-
titute an epithelial 'tree' in which some of the cells express
the introduced gene. This is a versatile model for studying
growth, development and tumourigenesis in the mammary
gland as a wide variety of genes can be introduced and their
effect on the epithelial cells determined in their natural tissue
environment.
The system has been used to investigate the effect of
several oncogenes on the growth and development of the
mammary gland. Introduction of the v-myc oncogene alone
led to a mild hyperplasia in the gland where the epithelial
ducts packed more closely than usual (Edwards, Ward &
Bradbury, 1988, Oncogene, 2, 407). v-Ha-ras alone seemed to
inhibit the growth of transplants as many mammary glands
into which v-Ha-ras-containing cells were transplanted were
devoid of epithelial growth. In those glands where there was
some growth it was often abnormal, resembling hyperplastic
alveolar nodules, a preneoplastic lesion of mouse mammary
gland. When both oncogenes were introduced simultaneously
tumours resulted in a high percentage of the animals (Brad-
bury, Sykes & Edwards, 1991, Int. J. Cancer, 48, 908). Other
oncogenes shown to have effects on the growth pattern in-
clude int-i which caused vigorous hyperplasia in which the
gland was packed with epithelium showing sidebranching like
early pregnancy.
The role of chromosome 17 in epithelial ovarian cancer
S.G.H. Russell', M. Murphy2, D. Bell2, P. Harkin2, R.J.
Atkinson2, W.S. Lowry2 and I. Hickey3
'Department of Medical Genetics, 2Department of Oncology,
3School ofBiology & Biochemistry, The Queen's University of
Belfast, N. Ireland.
Epithelial ovarian cancer accounts for approximately 5% of
all new cancers in the United Kingdom each year.
We have used allele loss studies to indicate areas of the
genome in which tumour suppressor gene inactivation may
contribute to this disease.
In a preliminary investigation of 20 tumours, we described
significant rates of allele loss from at least two loci on
chromosome 17'. Approximately 50% of tumours showed
loss from the p53 locus (17pl3) while 75% showed loss with
the probe pTHH59 (17q23-25).
We have now extended this investigation to a bank of 80
tumours and related allele loss at these two loci to his-
topathological type and stage of disease. Allele loss at p53
(17pl3) was observed in serous, mucinous and endometrioid
tumours but was more prevalent in stage III/IV disease than
stage I/II. Allele loss in the region of the probe pTHH59
17q23-25 was also observed in the three histological sub-
types and was high in both early and late stage disease.
We have used additional 17q probes to define the region of
the loss on this chromosome arm. Partial allele losses were
observed in 11 cases. The results are consistent with a target
gene mapping to the region extending between the markers
pTHH59 (17q23-25) and p05626 (17q25).
Reference
RUSSELL & Others (1990). Oncogene, 5: pl581-83.
FGF activity in conditioned medium derived from human breast
tissues
A. Yelland, Y.A. Luqmani, J. Smith & R.C. Coombes
CRC Laboratories, Department ofMedical Oncology, Charing
Cross Hospital, Fulham Palace Road, London W6 8RF.
A number of putative growth factors (GFs) have been imp-
licated in the maintenance and progression of breast cancer.
We have investigated the presence of fibroblast growth
factor-like (FGF-like) substances released from breast tissues
and cultured cell lines into serum free conditioned medium
after 24 and 72 h using the NR6 bioassay.
After 24 h the conditioned medium (CM) from cancers fell
into two distinct groups, one third (15/45) were found to
contain a high level of NR6 growth promoting activity,
whilst the other two thirds had low level activity. The
tumours with a high level of activity were associated with
vascular invasion (p = 0.04). However, after a further 48 h,
the CM from all cancers (n= 52) contained only low level
activity. In twenty-two cases this activity was found to be
heat stable and these cancers were significantly more likely to978 JOINT WINTER MEETING REPORT
have metastasised to the regional lymph nodes (p = 0.01).
CM (72 h) from adjacent-histologically-normal (AHN) tis-
sue was obtained in a similar manner to that for the cancers.
The growth promoting activity for both cancer and AHN
tissue was characterised using heparin affinity chromatog-
raphy, neutralising antibodies and western blotting. We
found evidence of both acidic and basic FGF-like activity.
CM from two cell lines also contained a peptide co-migrating
with authentic bFGF on SDS PAGE and which was detected
by antibodies to bFGF on western blotting.
These results suggest that both normal and malignant
breast tissues contain acidic and basic FGFs and that these
appear to be released into the extracellular environment.
Endothelin is a paracrine mitogen for human breast stromal
cells
K.V. Patel & M.P. Schrey
Unit of Metabolic Medicine, Chemical Pathology and Clinical
Endocrinology, St. Mary's Hospital Medical School, London
W2 JPG.
Human breast cancer cells have been recently reported to
produce endothelin (ET)-1 (Kusuhara et al., Cancer Res., 50,
3257, 1990). The function and regulation of ET-1 in the
neoplastic breast is unknown. The aim of the present study is
to assess the potential of ET-1 to act as a paracrine mitogen
for human breast stromal cells. We have also monitored the
ability of various hormones and growth factors to regulate
ET-1 production by human breast cancer cells. ET-1 produc-
tion by T47D cells was measured by radioimmunoassay and
I3H] thymidine incorporation into human breast fibroblast
DNA was measured in response to ET-1 and insulin-like
growth factor l(IGF-l).
Bombesin (0.1 jLM) and cortisol (1 gLM) stimulated maximal
respective increases in ET-1 release to 580% and 369% of
basal values (7.2 ± 0.4 fmol/106 cells) after 6 h. The responses
to cortisol and bombesin were additive. The response to
bombesin was dose-dependent with an ED50 around 1 nM
and was inhibited by the receptor antagonist [Leu'3-+-
CH2NH-Leu'4] bombesin. ET-1 (10 nM) and IGF-1 (10 ng/
ml) stimulated modest separate increases in DNA synthesis in
human breast fibroblasts of 35% and 71% respectively, but
together exhibited a strong synergistic response to 905% of
control values. In the presence of IGF-1, significant increases
in DNA synthesis were observed in response to 10 pM ET-1.
This in vitro study demonstrates the potential for bombesin
and glucocorticoid to regulate ET-1 production in human
breast cancer cells, which may in turn have a paracrine
influence on neighbouring stromal cell function.
This work is supported by the Cancer Research Campaign,
UK.
The B cell surface antigen, CD19, is involved in signalling entry
into apoptosis
C.D. Gregory & A.E. Milner
Department ofImmunology, The Medical School, Birmingham,
BI5 2TT.
The term 'apoptosis' describes a genetically-controlled prog-
ram of events which culminates in the self-destruction of
cells. The regulation of apoptosis is known to determine the
fate of a variety of cell types and inappropriate suppression
of the process could contribute significantly to oncogenesis. B
lymphocytes have the potential to enter apoptosis at stages of
their differentiation when control is required over numbers of
rapidly proliferating, genetically altered cells. These stages
are: 1) in the bone marrow during initial immunoglobulin
gene rearrangements, and 2) in the germinal centres of lym-
phoid tissue, during affinity maturation of antibody response.
Our studies have recently shown (Nature, 349, 612, 1991)
that Burkitt lymphoma (BL) cell lines which retain the ger-
minal centre B cell phenotype of the original tumour cells
readily enter apoptosis, whereas isogenic lines expressing
Epstein-Barr virus latent proteins do not. Using this model
system, we now show that BL cells can be triggered into
apoptosis through antibody-mediated ligation of their cell
surface CD19 antigen. CD19, a member of the immunog-
lobulin supergene family, is a 'pan-B' cell marker, being
expressed very early in B cell differentiation and retained
until the terminal plasma cell stage. Its function in signalling
entry into apoptosis therefore has important implications for
B cell physiology. Our studies further indicate that suscep-
tibility to CDl9-induced apoptosis is limited to a narrow
window of B cell differentiation and is significantly reduced
following expression of the bcl-2 oncoprotein.
Ras mutations as a prognostic indicator in malignant melanoma
D.C.Lewis',V.K. Shukla', N. Warren2, R.A. Padua2 & L.E.
Hughes'
Departments of Surgery' and Haematology2, University of
Wales College of Medicine, Heath Park, Cardiff CF4 4XN.
We have used the polymerase chain reaction and
oligonucleotide hybridisation to detect point mutations of N,
H, and K RAS in benign and dysplastic naevi, primary and
metastatic melanoma.
Mutations were observed in 6 out of 26 naevi (23%), 9 out
of 42 primary tumours (22%) and 9 out of 28 metastatic
melanomas (32%), with K12 being the most frequently
identified mutation. Of the 22 primary melanomas with
lymph node involvement, there were 9 mutations (41%), each
occurring in a separate patient. There were no patients in
which the mutation was maintained from the primary to the
secondary tumour. Of these 22 patients, those with a muta-
tion at some stage of the disease had significantly reduced
survival times of 25 months compared to 54 months in those
without mutations (p<0.05).
In the naevi all 6 mutations were found in the 9 removed
following a significant increase in size, the presence of RAS
mutations correlating strongly with clinical growth
(p<0.001). No correlation was found between age, sex, site,
tumour thickness or the predisposition to metastatic spread
and RAS mutations.
It appears that RAS mutations correlate strongly with
growth in melanocytic lesions and tend to be associated with
aggressive disease with a poor prognosis.
The E5 gene of human papiliomavirus type 16 can co-operate
with the epidermal growth factor receptor
R.J. Jewers, B. Kell & J.M. Best
The Richard Dimbleby Laboratory of Cancer Virology, St
Thomas' Hospital, London SEJ 7EH.
Human papillomavirus type 16(HPV-16) is strongly assoc-
iated with anogenital neoplasias. It is established that two
early genes, E6 and E7, encode oncoproteins that interact
with the cellular tumour suppressors p53 and pRB, respec-
tively. The function of another early gene product, E5, has
only recently been determined (Jewers et al., Eur. J. Cancer,
in press).
We have expressed the HPV-16 E5 gene in murine fibrob-
lasts and have shown anchorage independent growth and a
loss of contact inhibition, both indicative of transformation.
Exogenous epidermal growth factor (EGF) increases the fre-
quency and size of colonies formed in soft agarose by HPV-
16 E5 transfected 3T3 cells. In addition, HPV-16 E5 has a
mitogenic effect on serum starved cells that is stimulated by
exogenous EGF, with a resulting upregulation of the c-fosJOINT WINTER MEETING REPORT 979
gene. This suggests that HPV-16 E5 acts by increasing int-
racellular signals from the EGF receptor to the nucleus.
Expression of steroid and epidermal growth factor receptors in
MCF-7 cells resistant to multiple drugs
R.D.H. Whelan, S. McClean & B.T. Hill
Laboratory of Cellular Chemotherapy, Imperial Cancer
Research Fund, London WC2A 3PX.
Human breast tumours which are steroid receptor negative
and express increased levels of epidermal growth factor
receptor (EGFR) are associated with poor prognosis. Altered
expression of these receptors has also been associated with
the development of multidrug resistance (MDR) (Vickers et
al., Molecular Endocrinol., 2: 886-892, 1988). Since drug resis-
tance can be expressed following exposure of tumour cells
not only to antitumour drugs but also to X-irradiation we
have therefore determined the levels of oestrogen receptor
(ER), progesterone receptor (PR) and epidermal growth fac-
tor receptor (EGFR) in a series of vincristine (VCR) resistant
MCF-7 sublines derived following exposure to drug (MCF-7/
VCR), alternate drug and X-ray treatments (MCF-7 VCR/
DXR) or to fractionated X-irradiation (MCF-7 DXR/10).
These sublines exhibited resistance to VCR (4- to 14-fold)
and etoposide (2- to 3-fold). In contrast to X-ray pretreated
cells MCF-7/VCR sublines expressed the classical MDR
phenotype including cross-resistance to adriamycin and
overexpression of P-glycoprotein. This expression of MDR
was associated with a loss of detectable levels of ER and PR
and elevated levels of EGFR (10-fold) determined by ligand
binding assays. However, MCF-7/DXR1O cells retained
parental cell levels of ER (73 ± 14 fmoles/mg protein), PR
(215 ± 20) and EGFR (7 ± 1). In addition, X-ray pretreated
cells also proved sensitive to oestrogen and 4-OH tamoxifen
and expressed similar levels of the oestrogen regulated pS2
peptide to parental cells after oestradiol stimulation. These
studies indicate that ER, PR and EGFR are not consistently
modified in cell lines which expressed resistance to multiple
drugs.
The relationship between expression of epidermal growth factor
receptors by tamoxifen resistant and oestrogen independent
breast cancer cell lines and response to epidermal growth factor
B. Long, B.M. McKibben*, M. Lynch & H.W. van den Berg
Departments of Therapeutics and Pharmacology and
Medicine*, The Queen's University of Belfast, N. Ireland.
Positive epidermal growth factor receptor (EGFR) status of
primary human breast cancer has been reported to be a
powerful indicator of poor prognosis and intrinsic resistance
to hormonal therapy. In vitro experiments using cell lines
from a number of sources have indicated no clear relation-
ship between EGFR expression and response to EGF or
transforming growth factor a. We have previously reported
that tamoxifen resistant and oestrogen independent/
tamoxifen sensitive variants of the ZR-75-1 human breast
cancer cell line express markedly altered levels of EGFR
(Long et al., Br. J. Cancer, 63, Supplement XIII, 60, 1991).
In this study we have examined the proliferative response of
these cell lines to EGF under a variety of culture conditions.
ZR-75-1 cells express 4,340 ± 460 EGFR sites/cell and failed
to respond to EGF in serum-containing culture conditions.
In serum-free medium (SFR) containing insulin (5 x 10-7M)
and oestradiol (10-8M) cells proliferated more slowly but
again failed to demonstrate a consistent response to EGF.
The same results were obtained for the tamoxifen resistant
line (14,723 ± 2116 EGFR sites/cell) and the oestrogen
independent line (803 ± 161 EGFR site/cell). In SFM lacking
insulin or oestradiol ZR-75-1 cells failed to proliferate but
showed a marked dose-dependent growth stimulatory res-
ponse to EGF (0.01-100 ng/ml). In contrast the variant lines
continued to proliferate in the absence of insulin or oest-
radiol and exogenous EGF was without effect. Failure of the
oestrogen independent line to respond did not appear to be
the result of receptor occupation by autocrine growth fac-
tor(s) as neither acid washing or suramin treatment
uncovered further receptors. Whilst minimal receptor expres-
sion might explain the failure of this line to respond to EGF
an elevated level of EGFR typified by the tamoxifen resistant
variant did not confer sensitivity to exogenous ligand.
Autocrine/paracrine growth regulation by EGF and TGF- o in
human ovarian adenocarcinoma cell lines
A.J. Crew, J.M.S. Bartlett, W.N. Scott, E.P. Miller, G.J.
Rabiasz, S.P. Langdon & W.R. Miller
ICRF Medical Oncology Unit, Western General Hospital,
Edinburgh EH4 2XU.
In primary ovarian cancers, EGF receptors have been
detected in 40-70% of tumours and EGF and TGF-a
detected in 38% and 85% respectively. This coincidental
expression suggests that EGF and TGF-x may regulate
growth of ovarian cancer cells via an autocrine or paracrine
pathway.
In order to test this hypothesis of growth regulation via
EGF/TGF-oc, two human ovarian adenocarcinoma cell lines,
PEO4 and PEO14 have been studied as model systems. Using
an RNAse protection assay, the mRNA for TGF-a has been
detected in the PEO4 cell line, but is absent in the PEO14 cell
line, whereas the EGF protein has been detected in the
conditioned media of both cell lines by RIA, providing
evidence for the production of the factors. EGF receptors
have been identified on the two cell lines by immunohis-
tochemical techniques and ligand binding. In addition, the
growth of both cell lines is stimulated by EGF and TGF-x.
EGF causes a rapid down-regulation of EGF receptors in
both cell lines. Oestrogen also produces a decrease in EGF
receptor level in the oestrogen-sensitive oestrogen receptor
(ER)-positive cell line, PEO4, although this is less pro-
nounced and delayed compared to the effects of EGF. No
changes in the EGF receptor level were produced by oest-
rogen in the ER-negative PEO14 cell line. It is suggested that
since all the components of an EGF/TGF-x autocrine/
paracrine loop are present on both cell lines, these may be
potential important growth regulatory pathways in ovarian
cancer, and in tumours which are ER-positive, may be
influenced by oestrogen.
A comparison of two methods for the detection of epidermal
growth factor receptor
D.J. Hastrich, J.M. Dunn, P. Newcomb, S.Nicholson & J.R.
Farndon
Department of Surgery, Bristol Royal Infirmary, Bristol BS2
8HW.
Controversy continues about the value of Epidermal Growth
Factor receptor (EGFr) as a prognostic indicator in women
with breast cancer. It is difficult to compare one study with
another when the methods used vary in basic method. We
have ascertained EGFr status on 100 tumours by competitive
radioligand assay and by immunohistochemistry using the
monoclonal antibody to EGFr RI (Amersham). There was
no corelation between tumour grade or size and EGFr status
with either method. Of 54 tumours positive on the assay 40
were positive on immunohistochemistry and of 46 tumours
negative on assay. 41 were negative on RI staining; there was
a strong correlation between the two methods. If the assay is
assumed to be the gold standard, immunohistochemistry has980 JOINT WINTER MEETING REPORT
a specificity of 74% and a sensitivity of 89%. Only long-term
follow-up of these patients will determine whether this fall in
sensitivity adds or detracts from the prognostic value of
EGFr.
Inhibition of non-small cell lung cancer (NSCLC) cell pro-
liferation by intervention in the EGF receptor pathway
R. Hoffman & J. Donaldson
Department of Clinical Oncology, MRC Centre, Hills Road,
Cambridge CB2 2QH.
Autocrine growth stimulation by TGFa is implicated in the
proliferation of NSCLC cells. Intervention in this process
therefore represents a potential target for anti-cancer therapy.
We examined EGF receptor expression in 4 cell lines derived
from patients diagnosed with NSCLC (L23P and its multid-
rug resistant variant L23AR, MOR and BEN). Scatchard
analysis of competition curves between EGF and ['25I]EGF
indicated the presence of a single class of EGF receptor in
L23P, L23AR and MOR cells (Kd values 7-8 nM). BEN
cells did not contain detectable levels of EGF receptors.
Spent medium from L23P cells competed with ['25I]TGFx for
binding to A431 cells, indicating that an autocrine loop
involving TGFa and the EGF receptor exists in these cells.
The anti-proliferative effects of EGF/TGFa pathway
antagonists were assessed by the MTT assay following a 5d
exposure. Growth of all the cell lines in serum was inhibited
by suramin (IC50 values of 0.15-0.24 mM). The EGF recep-
tor tyrosine kinase inhibitor 3,4 dihydroxybenzylidene
cyanoacetamide inhibited growth of the cell lines in serum in
decreasing order of potency MOR>L23AR> L23P>BEN
(IC50 values 37, 47, 62 and 118 iM respectively). 3,4 dihyd-
roxybensylidene malononitrile, which is a 4-fold less potent
inhibitor of the EGF receptor kinase, inhibited all the cell
lines with similar potency. There was little growth inhibition
after Id. Growth inhibition by the tyrosine kinase inhibitors
of cells grown in a defined medium in the absence of
exogenously added growth factors was similar to growth
inhibition in serum. The weak EGF receptor tyrosine kinase
inhibitor 2 amino-4-(4-hydroxyphenyl)-1,1,3-tricyanobuta-
1,3-diene caused less than 50% inhibition of all cell lines at
concentrations up to 200 tM. These data indicate that agents
which inhibit signal transduction by the EGF receptor may
be useful anti-proliferative agents in EGF receptor-positive
NSCLC including cells expressing the MDR phenotype.
Rat mabs to the human EGFR receptor for therapeutic app-
lication
H. Modjtahedi, J. Styles, J. Sandle, G. Box, S. Eccles & C.
Dean
Institute of Cancer Research, Belmont, Sutton, Surrey, UK.
The receptor for epidermal growth factor (EGFR) and trans-
forming growth factor a (TGFa) are often overexpressed by
squamous cell and other carcinomas and these receptors may
therefore form targets for antibody directed therapy. We
have produced a series of rat mAbs that recognise the exter-
nal domain of the human EGFR using as immunogen either
the head and neck carcinoma LICR-LON HN5 or the breast
carcinoma cell line MDA-MB 468. All of these antibodies
immunoprecipitate the 17OkD EGFR and 10/15 antibodies
inhibit the binding of '25I-EGF to HN5, EJ and MDA-
MB468 cells. Competition analyses show that the latter
mAbs bind to three distinct epitope clusters on the EGFR.
These antibodies also block the EGF induced growth of
fibroblasts and more importantly inhibit the growth in vitro
of several squamous cell carcinoma cell lines (HN5, HN6,
MDA-MB 468 and A431). The extent of growth inhibition is
related to the number of receptors expressed and is greatest
with HN5 cells (5 x 106 EGFR/cell). Flow cytometric cell
cycle analyses using HN5 cells show that after incubation in
the presence of two of the mAbs (ICR16, rat IgG2a and
ICR62, rat IgG2b) the cultures show a marked decrease in
cells in the S and the G2 phases. At concentrations above
5nM these antibodies completely block the growth of HN5
cells in vitro. Antibodies ICR16 and ICR62 effectively supp-
ress the growth of HN5 tumour xenografts in athymic mice
when antibody treatment (total dose 3.0 mg/mouse) was
started at the time of tumour inoculation. Tumour growth
was suppressed also when treatment with these antibodies
was delayed until 9 days after tumour inoculation. The
greater efficiency of antibody ICR62 in vivo compared to its
activity in vitro relative to ICR16 suggest that the former
may also be acting via interation with immune effector cells
and/or host complement.
The c-erbB2 p185 as a target for antibody therapy in breast
cancer
S. Eccles, J. Styles, M. Valeri, A. Bakir, H. Modjtahedi, J.
Sandle & C. Dean
Institute of Cancer Research, Sutton, Surrey, UK.
The overexpression of receptors for epidermal growth factor
by squamous cell carcinomas and of the related proto-
oncogene c-erbB-2 (pl85) by adenocarcinomas may provide
useful targets for specific antibodies. The product of the
c-erbB-2 gene is overexpressed in some 20% of breast and
ovarian carcinomas and patients whose tumours overexpress
the c-erbB-2 P185 have a poor prognosis. We have prepared
a series of rat monoclonal antibodies that bind to one of five
non-overlapping epitope clusters on the external domain of
the c-erbB-2 P185. All of the antibodies immunoprecipitate
the 185 kD protein and none binds to the related EGF
receptor. One of these antibodies (ICR12, rat IgG2a) binds
to p185 in Western blots and stains formol-saline fixed
paraffin embedded material. This antibody, which is of high
affinity (0.2nM) has been found to localise specifically and
stably to xenografted breast and ovarian tumours in nude
mice (up to 20% injected dose/g) when labelled with Indium-
111, Iodine-125 or the positron emitter Iodine-124. Under
these conditions tumour uptake of a control, isotype matched
antibody was less than 4% i.d./g. Tumour xenografts of
5 mm diameter were successfully imaged at 24,48 and 120 h
using the RMH-ICR MUP-PET camera. ICR12 labelled with
Iodine-124 is currently being evaluated in an imaging trial in
patients with breast cancer at the Royal Marsden Hospital,
Sutton.